The recent interview with James Williams indicated the long term goal is to licence DMX200 and the patent to 1 or more big pharmas, then carry on using the Dimerix HIT platform to identify other opportunities (below) and do it all again.
See potential below....
Interview extract here:
http://finfeed.com/biotech/dxb/sear...ase-interview-dxb-md-james-williams/20160329/
In terms of the pipeline of opportunities after DMX200, they have various programs including investigating treatment for liver disease and cancer.
http://dimerix.com/technology/
The liver disease pre-clinical work is actually already in progress, has not really been promoted by the company, and early results are due in the next quarter too:
http://dimerix.com/wp-content/uploads/Bioshares636rbpDXB.pdf
Licensing or Selling, page-2
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
-0.010(2.20%) |
Mkt cap ! $247.9M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 45.8¢ | 43.8¢ | $701.3K | 1.564M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 111371 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 8072 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |